NEOVACS SA NEOVACS ORD SHS (0W8U.L)
- Previous Close
0.0106 - Open
0.0079 - Bid --
- Ask --
- Day's Range
0.0064 - 0.0079 - 52 Week Range
0.0064 - 99.0000 - Volume
455,418 - Avg. Volume
1 - Market Cap (intraday)
-- - Beta (5Y Monthly) -190.46
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of lupus erythematosus; and Phase IIa clinical trial for the treatment of dermatomyositis; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company was founded in 1993 and is based in Paris, France.
www.neovacs.com22
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0W8U.L
View MorePerformance Overview: 0W8U.L
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0W8U.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0W8U.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-8.42%
Return on Equity (ttm)
-104.43%
Revenue (ttm)
823.43k
Net Income Avi to Common (ttm)
-35.45M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
231.61k
Total Debt/Equity (mrq)
2.58%
Levered Free Cash Flow (ttm)
-4.04M